INTRODUCTION
Induction of labour involves the artificial initiation of uterine contractions prior to their spontaneous onset, leading to progressive dilatation and effacement of the cervix and delivery of baby. Women who require labour induction often present with unfavourable cervices which can lead to a prolonged and difficult induction. Pre-induction cervical ripening is often done to increase the likelihood of successful labour induction. Till 41 weeks of gestation, more than 15% of pregnancies remain undelivered. [1] [2] [3] [4] Induction rates range from10% to 25% in industrialized countries. 5 Induction of labour can be achieved by a variety of physical and biochemical stimuli designed for the purpose. However, approximately 20% of women having induction of labor end up with cesarean delivery. 6, 7 Hence, there is a keen interest in developing safer, most cost-effective and more efficient means for induction of labour. In this regard, synthetic prostaglandin has been used for labor induction since very long. Misoprostol, 8 an E 1 analogue has also been used extensively because of its low cost, easy availability, easy storage and effectiveness especially in low socioeconomic settings like ours. Though, it has been extensively studied but its usage is not yet licensed because of risk of uterine hyper-stimulation and its consequences. Therefore, we conducted this study to determine the efficacy and safety of Misoprostol for induction of labour in our set up.
SUBJECTS AND METHODS
This quasi experimental study was conducted at Labour ward of Aga Khan Maternal and Child Care Center (AKMCCC) Hyderabad, Sindh -Pakistan from September 2005 to May 2006. AKMCC is a private sector secondary level hospital with limited research facilities. Study subjects included 40 women with singleton pregnancy for induction of labour. Sampling strategy was non-probability convenient. Inclusion criteria were gestational age >36 weeks, cephalic presentation, patient having reassuring cardiotocograpghy and intact membranes. However, women with previous operative delivery, contraindicated to vaginal delivery and parity of more than 1 were excluded from the study. Multiparous women were excluded from the study because of higher risk of uterine rupture. After an informed consent, women were given 100 mgm of Tablet Misoprostol in the posterior vaginal fornix every 6 hours till 3 doses or initiation of active labour. Women were monitored with intermittent cardiotocography. Failure of Bishop's Score to rise by 2 or failure of established labour by 18 hours was taken as failure of induction. More than 4 uterine contractions of 40 seconds in 10 minutes were taken as hyperstimulation. Women with failed induction were offered a choice of being delivered by cesarean section or having another trial of induction following a rest period of 24 hours (provided fetal conditions permit).
RESULTS
In all, 40 women with different indications for induction of labour were enrolled for this study. Age range of the women was18-35 years ( Table I) . Twelve women (31.6%) delivered within 7-8 hours of initiation of active labour (Table II) . Seventeen (42.5%) women required 2 doses of 100 µg Misoprostol for induction of labour (Table III) . Women with Bishop's score 4 or less contributed 62.5%(25) of sample (Table IV) . Induction was failed in only 2(5%) women. Out of all women, 5 underwent cesarean section. Among these women, 2(5%) had induction failure, 2 underwent cesarean section due to fetal distress while one because of deep transverse arrest. Other complications were postpartum haemorrhage and hypertonous in 4(10%) women respectively whereas hypersystole in 2(5%) women. Neonatal hypoxia was observed in no any case. Labour was successfully completed in 35 (87.5%) women even when Bishop's score was less than 4 in 62.5% of women (Table V) . 
DISCUSSION
Labour induction is a very important part of obstetric care. Prostaglandin E 2 has been used effectively since 1968 for this purpose. Cost of prostaglandin E 2 is quite high compared to Misoprostol (E 1 ). [9] [10] [11] Misoprostol has been found safe in induction of labour in resource constrained hospital settings in developing countries like ours, using basic clinical tools for monitoring.
12-14 Stress of pregnancy and labour increases as women reach near term. Among cases of this study, more consciousness was also noted after 36 weeks of gestation regarding induction of labour on the expected date. The 5-8 hours duration of active labour in this study was quite satisfying and comparable with similar reports from other parts of the country [15] [16] [17] [18] as about 75% of women delivered with a divided maximum dose of 200 mgms. However, larger doses are reported to be safe for 2 nd trimester of pregnancy with good results. 19, 20 Ten women (25%) who received higher dose in this study showed hyper- tonous in 50% of cases but this responded well to simple analgesia. Those who did not respond to this higher dose were unable to respond to Dinoprostin as well and had operative delivery. 21 Misoprostol has proved to be more efficient in stimulating labour compared to Oxytocin and Dinoprostin 22 but safety still need to be proven. 23, 24 Repeated small doses of 50 microgram every 4 hours has been practiced with good results even in multiparous women 25 but we were cautious in using even low doses for multiparous women, being in a private hospital. Intracervical Misoprostol 50 microgram has resulted in 90% success rate in other studies 26 regardless of Bishop Score and now induction with greater dose is being tried. 27 In limited resource settings like ours where CTG is the only hi tech-monitoring tool, Misoprostol 100 microgram vaginal insertion resulted in short induction delivery interval and successful induction in majority of cases. Although, hypersystole and hyper tones were commonly observed but without any neonatal compromise. 28 Four (10%) patients had PPH which is also reported by others 29 , and need further study. Poverty and social inequalities among women and children are on increase even in the developed world. Providing a safe and cost effective health care should motivate us to conduct more studies using cost effective and efficient labour inducing agents. This seems near to women's perspective of maternity care. Modern maternity care demand women's participation and such studies no matter how small and lacking advanced statistical testing, can help not only in evidence building but, also in shared decision-making. We conclude that Misoprostol seems quite safe and effective for induction of labour at least in low parity women and in low socioeconomic settings. With its high success rate, it reduces LSCS rate and neonatal ICU admissions. The success rate no matter very tempting but one should take it with caution. The number of women was small in this study sample. There is tremendous need to carry out large studies to further prove safety and efficacy before its use as regular labour inducing drug.
